The therapeutic community is abuzz with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 agonist that’s demonstrating significant promise in clinical trials for treating obesity. Unlike some available weight loss solutions, retatrutide appears to deliver a more substantial decreas